6 results
The primary objective is to determine the efficacy of neo-adjuvant chemotherapy to reduce tumour size below 2 cm in diameter and thus enabling conisation.
The primary objective of this study is to determine the immune-activating capacity of treatment with pembrolizumab and carboplatin/paclitaxel in the neo-adjuvant setting of primary stage IV ovarian cancer as measured by the alteration in magnitude…
Main objective: response rate and tumour size reduction by chemotherapy
Main objective: response rate and tumour size reduction by neoadjuvant chemotherapy.
To assess the feasibility of preserving fertility in women with 2018 FIGO stage IB2 cervical cancer with lesions measuring >2 cm - <=4 cm.
To investigate whether (neo)adjuvant systemic treatment of intensified alkylating chemotherapy with peripheral stem cell rescue (mini-CTC) compared to AC-CP chemotherapy followed by 1-year olaparib monotherapy substantially improves overall survival…